The concentrations of moxalactam in human prostatic tissue, obtained by enucleation or transurethral resection, were measured in 10 patients after the intramuscular administration of two 500-mg doses. The average concentrations of moxalactam in prostatic tissue in the enucleated and transurethral resection specimens were 4.0 ,ug/g and 5.2 Iag/ml, and the ratios of the moxalactam concentrations in prostate to those in plasma were 0.24 and 0.31, respectively. The concentrations of moxalactam achieved in prostatic tissue after the administration of relatively low doses were greater than the minimum inhibitory concentrations of moxalactam for most common gram-negative pathogens. Concentrations of moxalactam in carefully obtained transurethral resection specimens were similar to those found in the enucleated specimens.
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Treatment of chronic bacterial prostatitis is hampered by poor penetration of most antimicrobial agents into prostatic secretions and tissue (13, 19, 23) . Therefore, even prolonged therapy during which high concentrations of antibiotics are attained in serum frequently fails to eradicate infection and prevent relapses of urinary tract infections caused by gram-negative bacterial pathogens (8, 11, 12, 16, 17) . Since moxalactam is significantly more effective in vitro than most other ,-lactams against common urinary pathogens (24, 27) , the penetration of this agent into the prostatic tissue of patients undergoing elective suprapubic or transurethral resection of the prostate (TURP) has been studied, with the results recorded in this report.
MATERiAL AND METHODS Patients. Five patients undergoing elective suprapubic prostatectomy and five patients undergoing TURP were studied. Informed consent, according to the guidelines of the Committee on Research Involving Human Subjects at the Albany Medical College, was obtained from all patients. The patients had no serious underlying disease. Their average age was 66 years (range, 55 to 82 years); their average weight was 75.5 kg (range, 65 to 86 kg). Urine cultures were negative on the day of surgery. Levels of creatinine in serum were <1.4 mg/100 ml. Drug adminstration. Moxalactam (500 mg) was administered intramuscularly 12 h before and at surgery.
Surgery and specimen preparation. TURP was performed using a Stern-McCarthy resectoscope, with the patient under spinal anesthesia. The sheath of the resectoscope was introduced through the urethra, the bladder was emptied of urine, and irrigation with 1% glycine was begun. Under direct inspection, a single 1.5-to 2.0-g specimen of prostatic adenoma tissue was excised, washed immediately in normal cold saline, and placed in a sterile container at 0°C.
Tissue obtained at suprapubic or retropubic enucleation of the prostate was immediately washed and cooled as described above, and random 0.5-to 1.0-g samples were removed from the subcapsular areas after inspection by the surgeon and the pathologist. The capsule was stripped, and the tissue was processed.
Prostatic tissue obtained by either surgical technique was washed in cold isotonic saline, snap frozen in C02-acetone, and stored at -70°C until assayed.
Plasma and urine samples were obtained immediately before TURP.
A moxalactam standard (Eli Lilly & Co., Indianapolis, Ind.) was prepared at a concentration of 1,000 Fg/ ml in phosphate buffer (pH 6.0) on the day of surgery.
Plasma, urine, and standard moxalactam samples were stored at -70°C until assayed.
In vitro studies. (i) Prostatic homogenates. Prostatic tissue was prepared by dicing frozen tissue and homogenizing it in cold phosphate buffer (pH 6.0) for 30 s in a tissue homogenizer (Tekmar Co., Cincinnati, Ohio). The homogenate was diluted with phosphate buffer to a concentration of 1 g of tissue per 10 ml of buffer. The homogenate was then spun for 30 min at 2,000 rpm, and the supernatant was used in the assay. Table 1 shows the concentrations of moxalactam in plasma and in prostatic tissue as well as the time of tissue sampling relative to the second dose of moxalactam. The concentrations of moxalactam in prostatic tissue obtained by enucleation ranged from 2.3 to 7.3 .g/g, and those in tissue obtained by TURP ranged from 3.6 to 6.9 Fg/g. The mean time after -the second dose of moxalactam was less and the plasma concentration was higher in the TURP group than in the patients undergoing prostatectomy by enucleation.
The ratios of the moxalactam concentrations in prostate to those in plasma ranged from 0. (22) .
Concentrations of moxalactam in prostatic tissue were similar in patients undergoing suprapubic prostatectomy or TURP. Although concentrations of moxalactam in plasma were higher in the TURP group of patients, this finding is most likely related to the shorter time between the administration of the drug and the time ofthe resection of the tissue.
The concentrations of moxalactam in prostatic tissue obtained by enucleation and TURP are markedly higher than the minimum inhibitory concentrations of most gram-negative urinary bacterial pathogens (24) . The similarity of con 
